前列腺癌P504S、p63及CK34βE12表达的研究

Expression of P504S,p63,and CK34bE12 in prostatic carcinoma

目的:探讨P504S、p63及CK34pE12表达在前列腺癌诊断和鉴别诊断中的价值。方法:采用免疫组织化学技术,检测P504S、p63及CK34βE12在各类前列腺病变中的表达。结果:102例前列腺癌中有92例表达P504S(90．2%);P504S在良性前列腺痛变上皮中表达率是8．2%(8/97),在前列腺高级别上皮内瘤(high grade intraepithelial neoplasias,HGPIN)中表达率是39．5%(15/38)。在切除的前列腺良性标本中,有＞2个腺体的p63表达缺失例数发生率为28．8%,明显低于CK34βE12的发生率53．0%(P＜0．05)。结论:P504S是前列腺癌敏感的生物学标志物;p63在前列腺基底细胞表达完整性方面优于CK34βE12;P504S和基底细胞标志物在临床病理诊断中联合应用可达到互补的作用。

Objective：To investigate the significance of expression of P504S, p63 and CK34βE12 in diagnosis and differential diagnosis of prostatic carcinoma. Methods： Immunohistochemical staining was used for detection of expression of P504S, p63, and basal cell-specific anti-cytokeratin antibody （CK34βE12） in various prostatic lesions. Results： P504S was expressed in 92 cases out of 102 patients with prostatic carcinoma （90.2%）. The positive rate of P504S expression was 8.2% （8/97） in benign prostatic lesions and 39.5 % （15/38） in high grade intraepithelial neoplasias （HGPIN）. In the removed benign prostatic specimens, the occurrence of lack of expression in more than two benign glands of p63 was significantly lower than that of CK34βE12 （28.8% vs 53%, P〈0. 05）. Conclusion： P504S is a sensitive biomarker of prostatic carcinoma; p63 is more sensitive than CK34βE12 in staining benign prostatic basal cells. Combined detection of P504S/basal cell biomarker may be of greater benefit in clinical diagnosis of prostatic carcinoma.